Intelligence Profile
Research Papers
The available research on this peptide combination is extremely limited, with only two recently published papers (both from 2026) addressing peptide therapies in musculoskeletal applications more broadly.
The first study, published in Sports Medicine, examined the "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance." However, specific details about study design, sample size, or findings regarding CJC-1295, Ipamorelin, or AOD-9604 individually or in combination are not available from the provided evidence.
The second paper, published in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, focused on "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions." This appears to be a review article discussing the broader landscape of peptide therapeutics in orthopedic medicine, though again, specific data on the compounds of interest is not provided in the available evidence.
Important limitation: No clinical trials specifically investigating CJC-1295 + Ipamorelin + AOD-9604 as a combination therapy were found in the clinical trial databases. The research base for this specific peptide combination appears to be very thin, with most available literature likely addressing these compounds individually rather than as a combined therapeutic approach.
More robust clinical research, including randomized controlled trials with adequate sample sizes, would be needed to establish the safety and efficacy profile of this peptide combination.